These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32928644)

  • 81. Letter to the editor, "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Koga S; Dickson DW; Wszolek ZK
    Parkinsonism Relat Disord; 2020 Oct; 79():130. PubMed ID: 32921567
    [No Abstract]   [Full Text] [Related]  

  • 82. Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease.
    Agin-Liebes J; Cortes E; Vonsattel JP; Marder K; Alcalay RN
    Parkinsonism Relat Disord; 2020 May; 74():76-77. PubMed ID: 31734038
    [No Abstract]   [Full Text] [Related]  

  • 83. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 84. Lack of central and peripheral nervous system synuclein pathology in R1441G
    Vilas D; Gelpi E; Aldecoa I; Grau O; Rodriguez-Diehl R; Jaumà S; Martí MJ; Tolosa E
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):832-833. PubMed ID: 30054313
    [No Abstract]   [Full Text] [Related]  

  • 85. Authors' replies to the comments of Koga et al. on "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Hickman RA; Vonsattel JP; Agin-Liebes J; Marder K; Alcalay RN
    Parkinsonism Relat Disord; 2020 Oct; 79():131-132. PubMed ID: 32928644
    [No Abstract]   [Full Text] [Related]  

  • 86. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
    Cookson MR
    Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
    Devine MJ; Lewis PA
    FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 92. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
    Konno T; Siuda J; Wszolek ZK
    Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 96. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Molecular basis of Parkinson's disease.
    Yang YX; Wood NW; Latchman DS
    Neuroreport; 2009 Jan; 20(2):150-6. PubMed ID: 19151598
    [TBL] [Abstract][Full Text] [Related]  

  • 98. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.
    Esteves AR; Swerdlow RH; Cardoso SM
    Exp Neurol; 2014 Nov; 261():206-16. PubMed ID: 24907399
    [TBL] [Abstract][Full Text] [Related]  

  • 99. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
    Covy JP; Giasson BI
    Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
    [TBL] [Abstract][Full Text] [Related]  

  • 100. New Frontiers in Parkinson's Disease: From Genetics to the Clinic.
    Shihabuddin LS; Brundin P; Greenamyre JT; Stephenson D; Sardi SP
    J Neurosci; 2018 Oct; 38(44):9375-9382. PubMed ID: 30381429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.